量子资源网

Insights

量子资源网 Insights: Your source for healthcare news, ideas and analysis.

量子资源网 Insights鈥攊ncluding briefs, webinars, and our podcast鈥攇ives you easy access to 量子资源网鈥檚 deep expertise, helping you stay current on the latest healthcare trends and topics. Search for a topic of interest or browse the latest insights below.

or
or
Receive timely expert insights on topics you care about.

1296 Results found.

Section 1115 Justice-Involved Reentry Demonstration Implementation Toolkit for Jail, Prison, and Juvenile Settings

Download

This toolkit provides a set of implementation checklists for Section 1115 Justice-Involved Reentry Demonstrations tailored to three carceral settings: jails, prisons, and juvenile facilities. Each checklist outlines operational tasks across core domains to support effective planning, coordination, and continuity of care pre- and post-release.

This toolkit is intended to provide information for jails, prisons, and youth detention centers in states contemplating submitting a 1115 Justice-Involved Reentry Demonstration, as well as states that have an approved demonstration. All states with approved demonstrations must provide core services, including care management for physical and behavioral health, medication assisted treatment for individuals when clinically indicated before release, and medication in hand at release. It is important to note that states may vary in their populations of focus, care management models, and processes for submitting claims. It is essential to cross-reference your state鈥檚 demonstration when planning to operationalize this initiative.

A Revenue Cycle Management Success Story: Advanced Diabetes Supply/US Medical Supply

Download

THE CLIENT

Advanced Diabetes Supply (ADS) acquired US Medical Supply (USMed), a Florida-based durable medical equipment provider, in 2021. At the time, ADS and USMed generated $400 million and $250 million in revenue, respectively. Over the next three years, the combined organization experienced rapid growth, reaching over $1 billion in annual revenue.

BACKGROUND

While the top-line growth was significant鈥59% over a three-year span鈥攃ash collections failed to keep pace. This created a classic case of an organization outgrowing its infrastructure. T he foundational tools, technology, and operational structure simply weren鈥檛 in place to support the accelerated growth, particularly on the revenue cycle side.

Compounding these challenges were issues stemming from the integration of the two companies, including billing inconsistencies and reimbursement delays. USMed, like many in the industry, was severely impacted by the Change Healthcare ransomware attack, disrupting billing and collections operations nationwide. At the time this project began, USMed was facing a $40 million backlog in accounts receivable and struggling to meet payroll. The revenue cycle team was understaffed and overwhelmed.

量子资源网 had previously performed a successful revenue cycle gap assessment at an ADS office in California. Based on those results, the newly hired CFO of ADS/USMed asked 量子资源网 to replicate the process for the Florida office. The goal: support the recently appointed VP of Revenue Cycle in stabilizing operations, implementing recommendations, and aligning practices to industry best standards.

TESTIMONIAL

鈥淲hen I stepped into the role, the environment was fragmented鈥 two teams on opposite coasts, multiple disconnected systems, and a lot of inefficiencies that came from rapid growth without the right infrastructure. It was a heavy lift to get our new leadership team fully ramped, but we never lost momentum thanks to the 量子资源网 team. 量子资源网 conducted a comprehensive RCM gap assessment that enabled us to clearly identify our key pain points. Through close collaboration with the RCM team at 量子资源网, we developed a strategic roadmap for success. 量子资源网 continued to provide valuable strategic guidance and transformation support throughout the project, contributing significantly to our progress. They stepped in as our interim leadership bench, brought structure to the chaos, and helped us stabilize operations quickly. I can directly attribute our ability to collect over $1.1 billion in revenue to the expertise and hands-on support we had from 量子资源网.鈥

Melanie Montero, Senior VP, Revenue Cycle, Advanced Diabetes Supply

APPROACH

量子资源网 completed a thorough gap assessment and was retained to lead the implementation phase. Key actions taken:

  • Developed a 6-month roadmap outlining both quick wins and long-term priorities.
  • Led a financial turnaround strategy centered on people, processes, and technology. 量子资源网 provided interim staffing, restructured workflows, and redesigned the revenue cycle team鈥檚 organizational chart.
  • Supported hiring efforts for key roles, including vendor selection and onboarding. A new financial reporting infrastructure was also introduced, replacing outdated systems with Power BI dashboards that now serve as the company鈥檚 central source of truth.
  • Identified payer-related issues and implemented solutions to drive improved cash collections using insights from Power BI.
  • Navigated the Change Healthcare crisis by facilitating a rapid transition to a new clearinghouse. A process that typically takes 4鈥6 months was completed in just over 30 days thanks to 量子资源网鈥檚 healthcare IT expertise.
  • Implemented preventative measures to improve claim accuracy, reduce denials, and ensure long-term revenue cycle stability.

RESULTS

Thanks to 量子资源网鈥檚 hands-on support, USMed experienced a measurable financial turnaround:

  • 12% YoY increase in cash collections, resulting in more than $38 million in additional revenue.
  • $16 million reduction in outstanding A/R within six months.
  • 38 new standard operating procedures created and rolled out.
  • Offshore training and onboarding of new RCM team members, including vendor management and leadership development.
  • Root-cause analysis and resolution of denial drivers and revenue leakage risks, with new upstream workflow improvement.
  • Full implementation of the Waystar billing system, replacing Change Healthcare. T his included Medicare claims monitoring tools, custom workflows for rejections, and 30+ custom rules that led to the recovery of $900K in payments over just five months.

量子资源网 can help other organizations identify gaps in their revenue cycle, and by working with us can expect to see improvements in denial rates and reimbursement. Our experts have decades of experience in every facet of the revenue cycle. They come from all sides of the healthcare industry, including providers, payers, managed care organizations, and more. From gap assessment to strategic planning to implementation and backfilling front or back-office operations, 量子资源网 can help you improve your company鈥檚 financial position. To learn more visit: healthmanagement.com/services/healthcare-revenue-cycle-management/

President Issues Executive Order Calling for Most Favored Nation Drug Pricing

Read Blog

On May 12, 2025, the President signed an Executive Order (EO), .鈥 The EO calls for or, in some cases, presumes a range of manufacturer, administrative and regulatory actions to reduce drug prices, but ultimate outcome remains unclear.

量子资源网 experts, including Leavitt Partners, an 量子资源网 company, are closely following executive agency and stakeholder responses to the EO. In this article, our experts summarize the EO and identify key considerations for healthcare stakeholders.

Policy Overview

Since his first administration, President Trump has consistently criticized disparities in brand-name prescription drug prices between the United States and other developed countries. In 2018, the previous Trump Administration issued a  to institute an International Pricing Index (IPI) model targeting Medicare payments for a subset of clinician-administered drugs. The IPI model would have set a Medicare payment amount for select Part B drugs at a lower amount to align with international prices and allow for negotiation of prices, while still providing a drug add-on payment to providers consistent with historical drug costs.  In November 2020, the administration issued an interim final rule (IFR) instituting an escalated version of this concept, entitled the . Both the IPI proposal and the MFN final rule, the latter of which was enjoined by the courts on largely procedural grounds and later rescinded by the Biden administration, would have been implemented under the Center for Medicare and Medicaid Innovation鈥檚 (CMMI) demonstration authority.

On May 12, 2025, the President signed an EO, , which reaffirms the Administration鈥檚 concerns regarding what it perceives to be American funding of pharmaceutical research and development 鈥渨hile foreign health systems get a free ride.鈥 In an effort to address the Administration鈥檚 concerns, the EO notes that the Administration 鈥渨ill take immediate steps to end global freeloading鈥 and that 鈥渟hould drug manufacturers fail to offer American consumers the most-favored-nation lowest price, my Administration will take additional aggressive action.鈥

The EO outlines efforts to implement this policy, including:

  • Trade Efforts.聽The US Department of Commerce and United States Trade Representative (USTR) are directed to ensure that foreign countries are not engaged in actions with the effect of forcing Americans to 鈥減ay for a disproportionate amount鈥 of R&D costs.
  • Direct-to-Consumer (DTC) Sales at MFN Price.聽The US Department of Health and Human Services (HHS) is directed to facilitate DTC sales programs for manufacturers to offer MFN prices.
  • MFN Targets.聽The HHS Secretary is directed to provide MFN targets to manufacturers within 30 days with the expectation that manufacturers will 鈥渂ring prices for American patients in line with comparably developed nations.鈥
  • If 鈥渟ignificant progress鈥 toward MFN pricing is not made, HHS will be directed to propose a rulemaking plan to impose it.
  • The order suggests that the HHS Secretary certify, on a case-by-case basis, that reimportation will pose no additional risk to public health and will result in savings, as well as to create standard mechanisms for importation. It is unclear how this direction aligns with the current statutory framework, which is focused on Canada.
  • Federal Trade Commission/Department of Justice Action.聽The EO calls for efforts 鈥渃onsistent with law鈥 to undertake enforcement action against anticompetitive practices identified in the prior drug pricing EO, including use of the Sherman Antitrust Act.

Key Considerations

At this stage, the scope and practical effects of the EO remain uncertain, as the administration has not yet provided details regarding the regulatory and subregulatory actions envisioned under the document. With respect to trade policy, for instance, the EO does not outline explicitly what particular tools it expects USTR or the Commerce Department to leverage in combating 鈥渇oreign freeloading.鈥

Similarly, the EO does not elaborate on the steps that the administration plans to take in 鈥渇acilitat[ing]鈥 voluntary MFN target pricing under DTC purchasing arrangements. Such efforts could theoretically bring waivers or other regulatory flexibilities to bear, or else they could take a more hands-off approach, simply encouraging drugmakers to take action on their own.

Without further clarifications around how the administration might define or assess 鈥渟ignificant progress鈥 towards MFN pricing targets on the part of manufacturers, nor the form, manner, or timeline that 鈥渁ggressive action鈥 in the absence of such progress might take, the EO serves principally as an illustration of the President鈥檚 posture, perspective, and priorities with respect to prescription drug affordability and access.

Even in the absence of immediate pricing or payment interventions, the EO could provide a preview of future executive actions aligned with the document鈥檚 focus. Such actions could include CMMI models building on the IPI or MFN initiatives from the first term, explicit trade negotiation priorities, regulatory measures related to DTC purchasing arrangements, FDA reimportation program flexibilities, or any number of other drug-related policies.

Our experts will continue to monitor these activities as they progress.

Connect With Us

For details regarding the EO and potential impact on the healthcare sector, contact our featured experts below at聽[email protected]

House Committees Consider Policies to Meet Budget Reconciliation Instructions

Read Blog

This week, key committees in the House of Representatives released recommendations for legislative language that meets their federal savings and spending targets required in the fiscal year (FY) 2025 budget resolution. On May 11, 2025, the House Energy and Commerce Committee released legislation鈥攁nd subsequently a substitute amendment鈥攖hat contains several substantive Medicaid proposals designed to address eligibility and enrollment; financing; fraud waste, and abuse; and to institute mandatory work and community engagement requirements and cost sharing. The Committee completed its markup on May 14, 2025, voting to approve the provisions in the substitute amendment.

The release of text and committee markups are key steps in Congress鈥檚 budget reconciliation process; however, proposals may change during Senate proceedings.

量子资源网 (量子资源网), and Leavitt Partners, an 量子资源网 company, are tracking these developments and analyzing the extensive health and health-related legislative text, including the Medicaid, Medicare, and Affordable Care Act (ACA) Marketplace proposals. Below, we review the status of congressional efforts and key policies.

Background

The budget reconciliation process is a powerful tool for enacting significant fiscal policy changes, as it allows for expedited consideration and passage of budget-related legislation. It has been used in the past to enact major tax reforms, healthcare legislation, and other important budgetary measures.

In 2025, Congress has been actively working to develop its budget bills through a series of steps. The House adopted a budget resolution on February 25, 2025, which sets the framework for federal spending, revenue, and the debt limit for fiscal year 2025 and outlines budgetary levels for the following years through 2034. The Senate passed an amended version of the budget resolution on April 5, 2025. The Senate鈥檚 amendments included reconciliation instructions that require $4 billion in gross deficit reductions and allow a $5.8 trillion net deficit increase. On April 10, 2025, the House agreed to the Senate鈥檚 amendments with a vote of 216鈭214. This agreement set the stage for the development of a reconciliation bill.

House Energy and Commerce Markup

On May 14, 2025, the House Committee on Energy and Commerce completed its second day of legislative language to comply with the Concurrent Resolution on the Budget for Fiscal Year 2025, voting to advance the proposals out of committee. The committee鈥檚 proposal excluded certain significant structural reforms that had generated concern among some members and stakeholders, such as broad reductions in the federal matching rate (enhanced federal matching assistance percentage (FMAP)) for Medicaid expansion populations, per-capita caps on federal Medicaid cost growth, or reductions in the safe harbor threshold for state Medicaid provider taxes. The proposal does, however, contain more than a dozen provisions that would reduce federal health care spending by $715 billion with the funding reductions mostly focused on Medicaid, which the Congressional Budget Office projects will reduce the federal share of Medicaid spending, including:

  • Adding mandatory work and community engagement requirements for individuals ages 19鈭64 without dependents, subject to exceptions for pregnant women, people who are medically frail, people with disabilities, people in compliance with other government program work requirements, people living in areas experiencing a temporary hardship, and other individuals
  • Adding cost sharing for beneficiaries in the expansion population who earn more than 100 percent of the Federal Poverty Level, not to exceed $35 per item or service
  • Pausing implementation of several final rules published during the Biden Administration, including: the final rule published September 21, 2023, 鈥淪treamlining Medicaid; Medicare Savings Program Eligibility Determination and Enrollment鈥; the April 2, 2024 rule, 鈥淪treamlining the Medicaid, Children鈥檚 Health Insurance Program, and Basic Health Program Application, Eligibility Determination, Enrollment, and Renewal Processes鈥; and the May 10, 2024, final rule, 鈥淢inimum Staffing Standards for Long Term Care Facilities and Medicaid Institutional Payment Transparency Reporting鈥
  • Adding provider screening requirements
  • Increasing frequency of eligibility redeterminations for certain individuals and adding enrollee address verification policies
  • Reducing expansion FMAP for certain states that provide Medicaid coverage to undocumented individuals and families, regardless of the source of funding
  • Preventing certain spread pricing arrangements in Medicaid between states and pharmacy benefit managers
  • Restricting funding for certain essential community providers that furnish family planning services, reproductive health, and related healthcare services
  • Ending a temporary increased FMAP to new states adopting Medicaid expansion, revising policies governing the use of Medicaid provider taxes, and payment limits for state directed payments

Committee Markups

Various other House committees have begun holding markups for the reconciliation package. The Committee on Ways and Means conducted its markup on May 13, 2025, to discuss its  of the reconciliation bill, which involves $4.5 trillion in deficit increases. The initial Ways and Means proposal did not include many significant healthcare proposals, but on May 12, 2025, the committee released a substitute amendment that includes several changes that would affect private insurance coverage and Medicare. Key provisions include:

  • Changes to Medicare and ACA premium tax credit (PTC) eligibility requirements related to immigration status
  • Improvements to ACA PTC eligibility verification checks
  • Changes to Health Savings Account flexibilities
  • Codification and renaming of individual coverage health reimbursement accounts, which serve as a defined contribution that employees can use to purchase insurance in the individual market

Other committees, such as the Education and Workforce, Judiciary, Armed Services, and Homeland Security Committees, also have conducted markups and approved their respective portions of the reconciliation bill.

Connect With Us

These steps are part of the ongoing process to finalize the budget and reconciliation legislation for FY 2025. Our federal policy experts with Leavitt Partners and across 量子资源网 are monitoring the legislative policies and ongoing negotiations in Congress and with the administration. They work with healthcare organizations and industry to plan for the range of scenarios and policies Congress is debating.

For more information about the impact of these policies, contact our featured federal policy experts聽below.

Webinar Replay – Ask 量子资源网 Experts: Behavioral Health Town Hall

Watch Now

This webinar was held on May 29, 2025.

In this dynamic and interactive Behavioral Health Town Hall hosted by 量子资源网 (量子资源网), our experts answered questions live on a wide range of critical topics, including:

  • Federal policy, personnel, and funding changes;
  • Emerging strategies for addressing social determinants of health, substance use disorder and crisis coordination (including 988);
  • Behavioral health revenue cycle management and alternative payment models; and
  • Innovations in addressing workforce shortages, integrated service delivery, digital mental health tools, and best practices for community mental health service delivery.

Health Policy in Maryland Amid Fiscal Uncertainty

Read Blog

The 2025 Maryland General Assembly session closed on April 7th. While the budget deficit consumed a large portion of legislative bandwidth, there was significant action on health-related programs, including supporting the implementation of the Centers for Medicare & Medicaid Services (CMS) All-Payer Health Equity Approaches and Development (AHEAD) Model, expanding access to care, paving a way for Prescription Drug Affordability Board (PDAB) expansion and increasing access to affordable insurance. The AHEAD Model is an innovation in healthcare finance that drives improvements in population health through increased investments in activities likely to improve health outcomes, and benefits hospitals that participate by providing stable funding through hospital global budgets.

Budget Deficits and Federal Funding Fears Limited New Spending

After intense debate and discussion, House and Senate fiscal leaders reached a budget agreement on the final day of session. From the beginning, significant projected general fund shortfalls existed in the current and future fiscal years. Primarily these shortfalls were due to higher than anticipated Medicaid enrollment and growth in obligations to fund K-12 education under the Blueprint for Maryland鈥檚 Future. Through a combination of actions including budget cuts, increasing hospital assessments to cover Medicaid costs, shifting costs to counties, and new taxes and fees, the budget passed along party lines. Due to concerns about the potential harm from federal budget cuts, particularly in the Medicaid program, the final plan includes a trigger provision requiring the Governor to engage lawmakers on solutions should federal funding to the state fall by $1 billion.  

The State Readies for the AHEAD model

Despite fiscal concerns, the General Assembly established two new funds, the Population Health Improvement Fund, and the Maryland Primary Care Program Fund, to support the implementation of the AHEAD model. Revenues to both funds are collected through an increase in hospital assessments.

  • The Population Health Improvement Fund will support efforts to reach statewide population health targets under the AHEAD model.
  • The Maryland Primary Care Program Fund will support the implementation of a Medicaid advanced primary care model and support primary care providers through investments in reimbursements for evaluation and management codes, care management fees to eligible practices, and quality incentives.

Supporting Access to Care

Lawmakers passed several bills aimed at increasing or protecting access to care.

  • The Preserve Telehealth Access Act of 2025 makes permanent provisions of law requiring reimbursement parity between telehealth and in-person services and includes 鈥渁udio-only鈥 services as telehealth under certain circumstances.
  • Legislation passed to address children and youth boarding in hospital settings beyond medical necessity. The bills define a 鈥減ediatric overstay鈥 and requires the Maryland Department of Health and the Maryland Department of Human Services to establish a pediatric overstay coordinator in each department to ensure that each patient is served in the least restrictive environment.

Several pieces of legislation passed to address behavioral health and substance use disorders including:

  • Eliminating the prohibition on using 9-1-1 trust fund dollars to support the 9-8-8 suicide prevention hotline, improving coordination between 9-1-1 and 9-8-8.
  • Establishing a buprenorphine training grant program to support training paramedics to administer the drug.
  • Further delineating uses of opioid restitution fund dollars and creating additional reporting requirements for the Office of Overdose Response.

Since the Dobbs decision, rolling back protections for abortion care in states, Maryland has been on the forefront of protecting reproductive freedom. Legislation passed establishing the Public Health Abortion Grant Program and Fund to support eligible organizations providing equitable access to abortion care services.

Regulating Prescription Drug Prices

Maryland established the Prescription Drug Affordability Board (PDAB) in 2019 joining ten other states in regulating the cost of prescription drugs through affordability boards. The goal of PDABs is to address high prescription costs by setting upper payment limits (UPLs) for drugs that cause or are likely to cause affordability challenges. Currently, Maryland鈥檚 PDAB is authorized to set UPLs for prescription drug products purchased by or on behalf of a unit of state or local government.  Legislation passed creating a pathway for the PDAB to set UPLs on prescription drug products paid for by additional state regulated payors if the board determines that the product has led or will lead to an affordability challenge.

Access to Affordable Health Insurance

The General Assembly made permanent the State-Based Young Adult Health Insurance Subsidy program and requires the Maryland Health Benefit Exchange in consultation with the Maryland Insurance Commissioner to establish and implement a state-based health insurance subsidy program for all individuals. The Maryland Health Insurance Protection Commission was reestablished to monitor federal changes that could impact coverage.

Change in Leadership at the Maryland Department of Health

During the busy legislative session, Secretary Laura Herrera Scott, MD, announced she was stepping down from her position as leader of the Maryland Department of Health. Former CMS administrator, Meena Seshamani, MD, was announced as Dr. Scott鈥檚 successor and sworn in on April 9th. Secretary Seshamani will be tasked with leading the transition from Maryland鈥檚 Total Cost of Care model to the AHEAD model and leading the department through a period of uncertainty and expected budget shortfalls.

Maryland State of Reform Conference to Cover Many of these Issues

These issues and more will be covered at the on June 12th at the Baltimore Marriott Waterfront. The day will include a panel of legislative leaders as well as sessions focused on the AHEAD Model, value-based care, behavioral health, public health, and prescription drug costs.

Governor Asa Hutchinson Announced as Keynote Speaker at 量子资源网 2025 Conference

Read Blog

We鈥檙e excited to welcome former Arkansas Governor Asa Hutchinson as the keynote speaker at the 2025 量子资源网 Conference October 14-16 in New Orleans, LA.聽 Governor Hutchinson brings over 40 years of leadership in law, national security, and public service. As the 46th Governor of Arkansas (2015鈥2023), he championed innovation in maternal healthcare, initiating programs and policies focused on improving maternal health outcomes during his time in office. He established the Maternal Life360Home program, expanding access to home visitations and intensive care coordination services for women with high-risk pregnancies and for children after birth, and improving the safety and wellbeing of children in foster care. He launched the Healthy Active Arkansas program, a 10-year plan to encourage schools and businesses to promote healthier eating and more activity.

His prior federal roles include Drug Enforcement Agency (DEA) Administrator, the first Under Secretary for Border and Transportation Security at the Department for Homeland Security (DHS), U.S. Congressman, and the nation鈥檚 youngest U.S. Attorney. We鈥檙e excited to welcome his perspective on advancing health outcomes across America.

In keeping with changes being made at the federal level affecting all aspects of the healthcare system, Governor Hutchinson will be discussing “The Policy and Politics of Making America Healthy.” In his address, he will share聽insights from his tenure in Arkansas, his perspective on effective health policy development, and the challenges to implementation at both state and federal levels. Join us for what promises to be an enlightening session as he explores the evolving relationship between federal and state governments and the opportunities for innovative health policy development that gives states more flexibility.

Don’t miss this opportunity to hear from one of our nation’s respected political leaders on issues that directly impact our industry and the health of Americans.

Date: October 14-16, 2025

Time: 8:30 a.m.

Location: Four Seasons New Orleans

Following the Governor鈥檚 talk, you will join with industry leaders to discuss new directions in payment and financing of publicly funded healthcare programs, community-level strategies designed to meet the needs of special populations, tailwinds driving the expanding universe of digital health policies, and innovations to strengthen access to behavioral health services. Come for the informative plenary sessions and workshops, explore strategies for navigating changes in funding, access, and coverage to ensure success in a shifting environment, and expand your network with federal and state policymakers, healthcare providers, insurers, philanthropists, and C-suite industry leaders. 

What鈥檚 Really Causing the Rise in Insurance Premiums, and What Can States Do 量子资源网 It?

Download

Healthcare cost increases are outpacing general inflation, which jeopardizes access to coverage and care, as well as investments in other priorities. As a result, states are looking for ways to reduce the cost burden for consumers, employers, and taxpayers. The State of Maine engaged Wakely Consulting Group, an 量子资源网 Company, to analyze historical medical trends and the associated impact on premiums in Maine鈥檚 health insurance market for the period of 2021 to 2025. The goal was to assess what factors are driving rising insurance costs. This project was supported by an 量子资源网 contract with Arnold Ventures, under which we provide technical assistance to states seeking to reduce healthcare cost growth.

Empowering Healthcare Leaders: Forging Insights and Collaborations at the National Medicare, Medicaid, and ACA Marketplace Event

Read Blog

As new federal priorities unfold鈥攑articularly for Medicare, Medicaid, and the Affordable Care Act (ACA) Marketplace鈥攈ealthcare stakeholders must anticipate and adapt to dramatic changes in funding, regulatory requirements, and technological advancements. 

In light of these shifting tides, you won鈥檛 want to miss 量子资源网 (量子资源网), 8th National Conference, , October 14-16, 2025, in New Orleans, LA. The 量子资源网 event will feature timely topics with insightful speakers who are at the center of decision making in government, healthcare service delivery, philanthropy, and industry. 

The conference will inspire thought-provoking conversations that will prepare you to navigate the rapidly changing healthcare landscape. The sessions will provide context for big ideas and workshops that will delve deeper into policy, strategy, and operations. Examples include:  

  • The Policy and Politics of Making America Healthy聽
  • When the Ground Shifts: Publicly Financed Health Coverage and Policy in Motion聽聽
  • Where Is Disruption Poised to Make Improvements in Healthcare?聽
  • Red, Blue, or Purple:鈥疊uilding Resilient Healthcare Systems to Improve Population Health鈥

The 量子资源网 conference welcomes all healthcare stakeholders. Each year we bring together federal and state policymakers, healthcare providers, insurers, philanthropists, and C-suite industry leaders to explore and discuss cross-cutting healthcare policy and operational issues.  

Networking Opportunities 

In addition to insightful sessions, the conference will offer numerous networking opportunities and . Attendees will have the chance to connect with peers, industry leaders, and policymakers during dedicated networking breaks, receptions, and informal gatherings in the vibrant city of New Orleans. These interactions will provide valuable opportunities to share experiences, discuss challenges, and explore potential collaborations. 

Learn more about the agenda, registration, and sponsorship on the conference site, . For sponsorship information contact Andrea Maresca, 量子资源网IS Managing Director.   

May 7, 2025

Empowering Healthcare Leaders: Forging Insights and Collaborations at the National Medicare, Medicaid, and ACA Marketplace Event

Read Roundup

The Evolving Behavioral Health Delivery System

Read Blog

During the month of May, 量子资源网 is featuring thought leadership and insights around Behavioral Health (BH) and changes within the BH delivery system in the U.S. Along with several presentations happening at NatCon25 in Philadelphia, May 5-7, we want to highlight some of the work done by 量子资源网 experts.  Starting us off, Josh Rubin, 量子资源网 Vice President, Client Solutions, has spent his career working with BH, intellectual and developmental disabilities, and child welfare service providers. In this post, he discusses the changing BH delivery system, and the issues surrounding the treatment of co-occurring mental health conditions.     

Ever since the 19th century when Dorothea Dix crusaded up and down the east coast encouraging state legislatures to fund state psychiatric hospitals, we have had separate systems for medical and mental health care. I mean Ms. Dix no disrespect, far from it; before her work we simply had no system of care for people with mental illnesses. Her contribution was immeasurable. But in 1963 when President Kennedy signed the Community Mental Health Act, it was an acknowledgement that the 鈥渙ut of sight, out of mind鈥 warehousing of people with mental illnesses in large state psychiatric hospitals was inappropriate and had to end.

Those of us who remember the heady days of the 1960s rightly celebrate the advance this represented in acknowledging the rights of people with mental illness to live in the community, and the opportunity it created for people with behavioral health conditions to build lives of dignity, productivity, and inclusion. And while we ought to celebrate that important advancement, we must nonetheless acknowledge that it maintained a separation between the underfunded mental health system, and a significantly better funded medical system. And thus, the community mental health system in America was built. It was designed to provide mental health care to the roughly 5% of the population that has a serious mental illness (SMI). In the nearly 60 years since, much has been done of which community mental health providers should be proud. We have transformed countless millions of people鈥檚 lives (and those of their families), built new program models, identified and implemented new practices, and built a service delivery system that offers a comprehensive continuum of care for people with SMI.

Unfortunately, that system was not built to address the needs of people with co-occurring mental health and substance use disorders (SUD), which is problematic because nearly half of people with a substance use disorder have a mental illness and nearly half of people with a serious mental illness have a substance use disorder. This is no surprise; the conditions are related. Some people with mental illnesses use drugs to manage their symptoms. Sometimes drug use can cause or exacerbate mental illnesses. In most cases, it is impossible to figure out where a mental illness ends, and a substance use disorder begins, or vice versa.

Yet in the U.S. we have always had separate service systems for these two conditions. Our systems grew up this way because although the stigma of mental illness is bad, the stigma of substance use is worse. While we have frequently been willing to address mental illnesses as health problems, we have long treated substance use disorders as criminal justice problems. We created community mental health centers. We launched a war on drugs.

The federal government provides two separate funding streams for states, one for mental health, the other for substance use disorder services. In many states there are separate agencies overseeing the two conditions, separate funding streams, and separate regulatory structures. Many providers respond to the funding and offer separate programs for one condition or the other.

This systemic failure leads every day to the death of Americans who have co-occurring mental health and substance use disorders but cannot access treatment for the two conditions together. Treatment works, and recovery is possible, but treatment works best when you are able to get treatment for your entire problem.

And just as the mental health and SUD systems were separated, they were both also segregated from the general healthcare delivery system. The stigma of our clients鈥 illnesses attached to us and our service system, so we were largely ignored by the healthcare delivery system and the people who funded and oversaw it.

While we have, as I said, much to be proud of, we cannot ignore the impact of our segregation. Our clients continue to die much younger than their peers. BH-related hospitalizations continue to increase. Overdose deaths and completed suicides, the worst possible outcomes, keep climbing, leaving incalculable suffering in their wake. And the financial costs of BH conditions continue to escalate, falling hardest on the historically underserved and marginalized communities that can least afford them. When America establishes a separate system, it isn鈥檛 equal; being ignored has consequences.

The good news? BH is not being ignored any longer. The bad news? BH is not being ignored any longer.

Healthcare policymakers have finally awakened to the reality that they will not be able to achieve their goals of better outcomes, lower costs, and improved customer service unless they address the BH needs of their populations. They are figuring out that everyone needs behavioral healthcare, and that a dichotomy that focuses BH care only on those with the most significant BH issues is ill serving. They are coming to understand that the skills, capabilities, and expertise of community BH providers have extraordinary value. It鈥檚 nice to be acknowledged and invited to help.

But it鈥檚 not all good news, because while being ignored left us underfunded and disrespected, it also protected us. Now that hospitals (which have been buying up outpatient practices at a remarkable pace) have started opening up BH services, we must compete with their deep pockets. And private equity (with even deeper pockets) has increased the pace at which they are acquiring BH providers, forcing additional competition on us. We are not even safe from our own phones. 10,000 mental health apps in the app store offer our clients a totally different paradigm for care, much of it lacking any evidence-based foundation. This makes it more dangerous for our clients, not less competitive for BH providers.

This environment requires fundamental changes in the way BH providers operate. We need new models of care that better meet the needs of the people we serve. Certified Community Behavioral Health Clinics (CCBHCs) are a step in the right direction, but they鈥檙e not a significant change in the service delivery model. If you look at the history of the BH system in America, from Dorothea Dix through today, you will see that the movement has been consistently in the same direction 鈥 inward. We have moved out of the hospitals in the countryside into clinics in the neighborhood. We have slowly chiseled away at the barriers dividing mental health from substance use disorder services. We have patiently worked to integrate with our health care colleagues. Now things are accelerating, and the pace of change is scary, but we should embrace the opportunity. We have a once in a lifetime chance to build something new, better, more effective.

Ready to talk?